Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.

Blood advances - 22 Aug 2023

Schulz Eduard, Aplan Peter D, Freeman Sylvie D, Pavletic Steven Z

Abstract excerpt

Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic mutations that are known or suspected to be oncogenic in the malignant cells. The genetic risk stratification of MDSs has evolved substantially with the introduction of the clinical molecular international prognostic scoring system, which establishes next-generation sequencing at diagnosis as a standard of care. Furthermore, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphoma Diagnosis and Treatment

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Neoplasm, Residual

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37267435
DOI: 10.1182/bloodadvances.2023010098
PMCID: PMC10432617

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.PMID 37267435Read ↗

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesSemantic proximity Read ↗

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Semantic proximity Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Semantic proximity Read ↗

Current state of prognostication and risk stratification in myelodysplastic syndromes.Semantic proximity Read ↗

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.Semantic proximity Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.Semantic proximity Read ↗

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.Semantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.